• Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Cision Canada
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • Analytics
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • Analytics
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Health Canada Approves ACTEMRA® (tocilizumab) for Canadians Living with Giant Cell Arteritis (GCA)


News provided by

Roche Canada

Nov 02, 2017, 08:00 ET

Share this article

Share this article


ACTEMRA® is the first non-steroid treatment designed to directly target the interleukin-6 (IL-6) receptor, offering a new option to treat GCA1

MISSISSAUGA, ON, Nov. 2, 2017 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that Health Canada has approved ACTEMRA® (tocilizumab) for the treatment of adult patients with giant cell arteritis (GCA).2  The approval was based on the outcome of the phase III GiACTA study, which showed that ACTEMRA, initially combined with a six-month steroid taper, sustained remission at one year in 56 per cent and 53 per cent of patients (with the weekly and bi-weekly doses respectively), compared to 14 per cent of patients in the placebo arm with a six-month steroid taper given alone.3

ACTEMRA is designed to directly target the interleukin-6 (IL-6) receptor, a protein that is made by the immune system, which the body uses to manage infections and plays a major role in the signs and symptoms of GCA.4 There have been no new treatments in more than 50 years.5,6

"When GCA is diagnosed too late or left untreated, it can cause serious, even potentially life-threatening, complications," says Dr. Christian Pagnoux, Internal Medicine Specialist and Rheumatologist at Mount Sinai Hospital in Toronto. "Treatment of GCA patients was limited to high-dose, long-duration steroids, and relapses were almost constant. The approval of Actemra provides physicians in Canada with a new treatment option."

GCA is the most common form of vasculitis that occurs in adults. It is caused by inflammation of the lining of the arteries.7 The disease often affects the arteries in the head, specifically around the temples and if GCA is left untreated, it can lead to stroke or blindness.8 Generally, GCA affects adults older than 50 years of age and is three times more likely to occur in women than in men.9 GCA causes headaches, visual impairment, vision loss, claudication (cramping caused by lack of blood flow)10 of the jaw, arms and legs,11 and can lead to aortic aneurysm, myocardial infarction, and stroke.12

About the Health Canada Approval
The approval of ACTEMRA (tocilizumab) for the treatment of adult patients with giant cell arteritis (GCA) was based on the randomized, double-blind, placebo-controlled, phase III GiACTA study. The GiACTA study investigated whether ACTEMRA resulted in higher rates of sustained glucocorticoid-free remission of GCA in comparison to placebo through a period of 52 weeks.13

The GiACTA study evaluated the safety and efficacy of ACTEMRA for the treatment of GCA in 251 patients with new-onset or relapsing GCA (cranial GCA and large-vessel vasculitis) who were enrolled and assigned to one of four treatment arms. The study consisted of a 52-week blinded period (Part 1), followed by a 104-week open-label extension (Part 2). Relationships between ACTEMRA concentrations to safety and efficacy endpoints were assessed. The purpose of Part 2 is to describe the long-term safety and maintenance of efficacy after 52 weeks of ACTEMRA therapy, to explore the rate of relapse and the requirement for ACTEMRA therapy beyond 52 weeks, and to gain insight into the potential long-term steroid-sparing effect of ACTEMRA. Two subcutaneous (SC) doses of ACTEMRA (162 mg every week and 162 mg every other week) were compared to two different placebo randomized control groups 2:1:1:1. All patients received background glucocorticoid (prednisone) therapy. Each of the ACTEMRA-treated groups and one of the placebo-treated groups followed a pre-specified prednisone-taper regimen over 26 weeks, while the second placebo-treated group followed a pre-specified prednisone-taper regimen over 52 weeks designed to be more in keeping with standard practice. 

The overall safety profile observed in the ACTEMRA GCA study was, in general, consistent with the known safety profile of ACTEMRA, including upper respiratory tract infections (common cold, sinus infections) headaches, and increase in blood pressure. The most common serious infections included pneumonia, urinary tract infection, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis and bacterial arthritis. Opportunistic infections including tuberculosis, cryptococcus, aspergillosis, candidiasis, and pneumocystosis were reported with ACTEMRA.14

No new safety signals were observed with ACTEMRA in the GiACTA study. There was no difference in safety profile between the arms of the study. ACTEMRA did not add to the safety profile of a six-month steroid taper. The safety of subcutaneous ACTEMRA has been studied in the phase III study GiACTA study in 251 GCA patients. While the overall safety profile observed in the ACTEMRA treatment groups was generally consistent with the known safety profile of ACTEMRA in other indications, there was an overall higher incidence of infections in GCA patients relative to rheumatoid arthritis (RA) patients.15

About ACTEMRA
ACTEMRA (tocilizumab) is a recombinant humanized anti-human IL-6 receptor monoclonal antibody of the immunoglobulin IgG1κ (gamma 1, kappa) subclass with a typical H2L2 polypeptide structure. ACTEMRA is composed of two heterodimers, and each of the heterodimers is composed of a heavy (H) and a light (L) polypeptide chain. Each light chain and heavy chain consists of 214 and 448 amino acids, respectively. The four polypeptide chains are linked intra- and inter-molecularly by disulfide bonds. ACTEMRA has a molecular weight of approximately 148 kDa.16

ACTEMRA is administered through subcutaneous (SC) injection and is supplied as a sterile yellowish, preservative-free liquid at a concentration of 162 mg/0.9 mL. Ready-to-use, single-use pre-filled syringes with needle safety device are available.17

About Roche
Headquartered in Basel, Switzerland, Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Roche Canada was founded in 1931. The company employs over 1,000 people across the country, with its pharmaceuticals head office located in Mississauga, Ontario, and diagnostics division based in Laval, Quebec. Roche Canada is actively involved in local communities, investing in charitable organizations and partnering with healthcare institutions across the country. For more information, visit www.rochecanada.com. 

All trademarks mentioned are the property of their respective owners.

© Copyright 2017; Hoffmann-La Roche Limited

REFERENCES
___________________________________________
1 Stone, JH. Trial of Tocilizumab in Giant-Cell Arteritis. July 27, 2017. 317.4
2 ACTEMRA (tocilizumab) Product Monograph; October 27 2017.
3 Stone, JH. Trial of Tocilizumab in Giant-Cell Arteritis. July 27, 2017. 317.4
4 ACTEMRA (tocilizumab) Product Monograph; October 27, 2017.
5 Borchers AT, et al. Giant cell arteritis: A review of classification, pathophysiology, geoepidemiology and treatment. Autoimmunity Reviews. 2012; 11:A544-5554.
6 Ponte C, et al. Giant cell arteritis: Current treatment and management. World J Clin Cases. 2015; 3(6):484-494.
7 The Johns Hopkins Vasculitis Center. Types of Vasculitis: Giant Cell Arteritis. https://www.hopkinsvasculitis.org/types-vasculitis/giant-cell-arteritis/. Last Accessed October 13, 2017
8 Mayo Clinic. Diseases & Conditions: Giant Cell Arteritis. 
 http://www.mayoclinic.org/diseases-conditions/giant-cell-arteritis/basics/definition/con-20023109. Last Accessed Oct 3, 2017.
9 The Johns Hopkins Vasculitis Center. Types of Vasculitis: Giant Cell Arteritis.
https://www.hopkinsvasculitis.org/types-vasculitis/giant-cell-arteritis/. Last Accessed October 13, 2017
10 Mayo Clinic. Disease & Condition. Claudication http://www.mayoclinic.org/diseases-conditions/claudication/basics/definition/con-20033581. Last Accessed Oct 3, 2017
11 Mayo Clinic. Disease & Conditions: Polymyalgia Rheumatica
http://www.mayoclinic.org/diseases-conditions/polymyalgia-rheumatica/basics/definition/con-20023162. Last Accessed October 3, 2017
12 Stone, JH. Trial of Tocilizumab in Giant-Cell Arteritis. July 27, 2017. 317.4
13 Ibid
14 ACTEMRA Product Monograph. October 27, 2017
15 ACTEMRA Product Monograph. October 27, 2017
16 Ibid
17 Ibid

SOURCE Roche Canada

For further information: Ashley Iyer-Dhillon, Roche Canada, T: 416-561-3286, E: [email protected]

Modal title

Organization Profile

Roche Canada

    Also from this source

  • COLUMVI® (Glofitamab for Injection) Receives Health Canada Authorization with Conditions for Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

  • Roche Canada Announces Purchase Agreement with the Government of Canada for ACTEMRA® IV (tocilizumab for injection) for Treatment of Adult Patients with COVID-19

  • Health Canada Authorizes POLIVY® (polatuzumab vedotin for injection) for the First-Line Treatment of Adults With Large B-Cell Lymphoma

Contact Cision

  • 877-269-7890
    from 8 AM - 10 PM ET

  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2023 CNW Group Ltd. All Rights Reserved. A Cision company.